Neoadjuvant Chemotherapy plus Camrelizumab for Locally Advanced Cervical Cancer (NACI study)
Release date:
2023-10-12
Description:
We conducted a multicenter, phase 2 study to investigate the efficacy of neoadjuvant chemo-immunotherapy (NACIT) for LACC. Eligible patients underwent one cycle of priming chemotherapy followed by two cycles of combination chemotherapy with camrelizumab. The primary endpoint included the objective response rate, while key secondary endpoints were pathological complete response (pCR), patients requiring postoperative adjuvant therapy (PAT), and safety profiles. Exploratory endpoints were pre-treatment biomarker for response and dynamic panoramas of intratumoral infiltrating immune cells. This study is registered with ClinicalTrials.gov, NCT04516616.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA005122.xlsx